SAB Biotherapeutics Inc SABS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SABS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.01
- Day Range
- $4.10–4.39
- 52-Week Range
- $4.00–11.90
- Bid/Ask
- $3.85 / $4.25
- Market Cap
- $39.21 Mil
- Volume/Avg
- 4,877 / 13,771
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 57
Valuation
|
Metric
|
SABS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SABS
Financial Strength
|
Metric
|
SABS
|
|---|---|
Quick Ratio | 5.23 |
Current Ratio | 5.45 |
Interest Coverage | −134.68 |
Quick Ratio
SABS
Profitability
|
Metric
|
SABS
|
|---|---|
Return on Assets (Normalized) | −72.32% |
Return on Equity (Normalized) | −118.13% |
Return on Invested Capital (Normalized) | −100.73% |
Return on Assets
SABS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fwtqbzdmb | Rmprc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qjsdmdxm | Ghgsjq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vwdksxts | Cjtsrc | $97.8 Bil | |
MRNA
| Moderna Inc | Drkxxks | Jnvtk | $41.3 Bil | |
ARGX
| argenx SE ADR | Jzrjsdn | Ctjkf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xwcfmcyw | Bvbwn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dclkkdl | Lrscvs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hfkxrhkz | Vtkvjvg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Swpclhjtbz | Dwlgw | $12.5 Bil | |
INCY
| Incyte Corp | Skrfcqhvd | Cyymsmg | $11.6 Bil |